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Abstract
Background: Inconsistent trends in HPV prevalence by age have been described in Africa. We examined the age
prevalence pattern and distribution of 37 HPV-DNA types among urban Nigerian women.
Methods: The study population was a sample of 278 women who presented to cervical cancer screening
programs in Abuja, Nigeria, between April and August 2012. Using a nurse administered questionnaire, information
on demographic characteristics and risk factors of cervical cancer was collected and samples of cervical exfoliated
cells were obtained from all participants. Roche Linear Array HPV Genotyping Test® was used to characterize
prevalent HPV and log-binomial regression models were used to examine the association between potential correlates
and the prevalence of HPV infection.
Results: The mean age (SD) of the women enrolled was 38 (8) years. The overall prevalence of HPV was 37%. HPV 35
was the most prevalent HPV type in the study population. Among women age ≤ 30 years, 52% had HPV infection
compared to 23% of those women who were older than 45 years (p = 0.006). We observed a significant linear
association between age and the prevalence of HPV infections. The prevalence ratio (PR) and 95% confidence interval
(CI) was 2.26 (1.17, 4.34) for any HPV infection, 3.83 (1.23, 11.94) for Group 1 HPV (definite carcinogens), and 2.19
(0.99, 4.84) for Group 2a or 2b HPV (probable or possible carcinogens) types, among women aged 18–30 years,
compared to women who were older than 45 years.
Conclusion: The prevalence of HPV infection was highest among younger women and decreased steadily with age
among this population of urban Nigerian women.
Keywords: HPV infection, Prevalence, Nigeria
Background
Human papilloma viruses (HPV) are small DNA vi-
ruses, of which there are several types associated with
benign and malignant conditions of the cervix, penis,
vulva, vagina, anus and oropharynx [1,2]. These viruses
are ubiquitous and most women in the world are prob-
ably infected with at least one type of HPV during their
sexual life giving a point prevalence of 10.1% [3]. The
Population Attributable Fraction of HPV associated
cancer varies from 14.2% in sub-Saharan Africa and
15.5% in India to 1.2% in Australia/New Zealand and
1.6% in Northern America [2].
Previous studies have shown that the prevalence of
HPV infection rises soon after the onset of sexual activ-
ity [4,5] and attains the highest value in adolescence and
early adulthood after which it declines during the second
and third decades of life [6]. While there seems to be a
clear peak in HPV prevalence in younger women in
Asia, Europe and Northern America, with a downward
trend as age increases, age-specific HPV prevalence data
from Central and South America appears to follow a
slight U-shaped curve [7].
In Africa, the age-specific prevalence of HPV differs
across countries. HPV prevalence was highest in younger
women and decreased steadily with age in Kenya, Uganda
and Zimbabwe [8-10] but generally reached a plateau at
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[11,12]. Whereas in Senegal, South Africa and another
study from rural Nigeria, the peak prevalence in young
women was accompanied by a second but smaller increase
in prevalence among older women [13-16]. In Gambia,
HPV prevalence remained relatively constant among women
aged 15 to 54 years [17]. The reason for these different age
prevalence patterns in Africa remains unclear. Possible rea-
sons include variations in sexual behavioral practices, sexual
hygiene, co-morbidities, polygamy, male sexual partner
behavior and male circumcision [15,16,18].
In this study, we examined the age prevalence pattern,
distribution and socio-demographic correlates of HPV
t y p e sa m o n gw o m e ni na nu r b a n ,e t h n i c a l l yd i v e r s e
population in Central Nigeria.
Methods
Study population
Between April and August 2012, we enrolled women from
cervical cancer screening clinics at National Hospital,
Abuja and University of Abuja Teaching Hospital, Nigeria.
Abuja is the Federal Capital of Nigeria and it is located in
the central part of the country. Its population is comprised
of individuals from almost all ethnic groups in Nigeria,
thus it is the most ethnically diverse city in the country
[19]. The study participants were 18 years or older, did
not have a history of hysterectomy, not pregnant and had
engaged in vaginal sexual intercourse. Interviewer adminis-
tered questionnaires were used to collect data on socio-
demographic characteristics, sexual and reproductive
histories. Samples of exfoliated cervical cells were ob-
tained from the cervical os with a cervical brush, which
was stored in Thinprep® at −80°C until processing for
HPV genotyping.
HPV detection by genotyping
HPV DNA was extracted using Gentra Puregene Cell
Kit® according to the manufacturer’s instruction. HPV
genotyping was done using Linear Array HPV genotyp-
ing test® (Roche Diagnostics), a qualitative in vitro test
which utilizes amplification of target DNA by the
Polymerase Chain Reaction and nucleic acid hybridization,
and detects 37 HPV genotypes - (6, 11, 16, 18, 26, 31,
33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61,
62, 64, 66, 67, 68, 69, 70, 71, 72, 73 (MM9), 81, 82
(MM4), 83 (MM7), 84 (MM8), IS39, and CP6108. It
has been validated and offers a reliable and sensitive
approach for HPV DNA detection and genotyping in
cervical specimens, using standardized quality-controlled
reagents [20-23].
We classified HPV types according to the World Health
Organization International Agency for Research on Can-
cer (IARC) Monographs Working Group assessment of
the carcinogenicity of different HPV types [24]. HPV types
were classified as follows: definite carcinogens (group 1),
HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59; Prob-
able carcinogens (group 2a), HPV 68; and Possible carcin-
ogens (group 2b), HPV 6, 11, 26, 40, 42, 53, 54, 55, 61, 62,
64, 66, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39 and
CP6108.
Statistical analysis
Descriptive analyses were performed to characterize the
sampled population. Student t-tests were used to assess
differences in the distribution of continuous variables
between groups while χ
2 and Fishers exact tests were
used for categorical variables. We created age categories
as follows: ≤ 30, 31 – 35, 36 – 40, 41 – 45 and>45 years
and calculated the Prevalence Ratio (PR) and 95% confi-
dence intervals (CI) by age categories and by HPV group
classification using univariate and multivariable log-
binomial regression models. In separate models, we ex-
amined the association between HPV positivity and the
following covariates: age, marital status, age at sexual initi-
ation, total number of sexual partners, HIV status, contra-
ceptive use, douching and body-mass index (BMI). To test
for a linear trend, we assigned each age category the me-
dian value and modeled this variable as a continuous vari-
able. All P-values were 2-sided and the analyses were
performed using SAS 9.3 for UNIX statistical software.
Ethics
The study was conducted according to the Nigerian Na-
tional Code for Health Research Ethics and the Declar-
ation of Helsinki. Ethical approval to conduct this study
was obtained from the IHVN Health Research Ethics
Committee and the University of Maryland, Baltimore, In-
stitutional Review Board. Informed consent was obtained
from all participants before enrollment in the study.
Results
A total of 278 participants were enrolled in this study.
We excluded 3 persons who had missing data on HPV
genotype or several demographic variables, data from
275 participants were available for analysis. The mean
age (SD) of the participants was 38 (8) and the median
age (inter-quartile range) was 37 (31–42) years. Table 1
describes the demographic characteristics of the study
participants.
T h ep r e v a l e n c eo fa n yo ft h e3 7H P Vt y p e si nt h es t u d y
population was 37% (101/275). Group 1 HPV types (defin-
ite carcinogens) were found in 22% (61/275) of the study
participants. HPV 35, a group 1 type, was the most preva-
lent type of HPV found in this study, it was found in 5%
(14/275) of the women studied. Other group 1 HPV types
found among the women studied were HPV 56, 58, 45 and
59 in decreasing order of prevalence. The prevalence of
HPV16 and 18 in this population was low; HPV 16 was
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Age strata (years)
Characteristics Total ≤ 30 31 - 35 36 - 40 41 - 45 > 45 P-value
n=275 n=64 n=63 n= 57 n=56 n= 35
Median (Inter-quartile range)
Age (years) 37 (31–42) 28 (26–29) 33 (32–35) 38 (37–39) 43 (42–44) 49 (47–53)
Age at sexual initiation 19 (18–22) 19 (17–21) 20 (18–23) 19 (17–22) 20 (18–22) 19 (18–21) <0.001
Total sex partners 3( 1 –4) 2 (1–4) 3 (2–5) 3 (1–3) 2 (1–5) 2 (1–3) <0.001
BMI (kg/m
2) 27 (22–31) 22 (19-27 25 (22–29) 27 (24–32) 29 (25–33) 31 (29–36) <0.001
n (Percentage)
Education 0.15
- Primary 38 (14) 11 (17) 8 (13) 10 (17) 3 (5) 6 (17)
- Secondary 191 (69) 49 (77) 42 (67) 38 (67) 39 (70) 23 (66)
- Tertiary 46 (17) 4 (6) 13 (20) 9 (16) 14 (25) 6 (17)
Marital status 0.41
- Married 169 (61) 34 (53) 38 (60) 40 (70) 36 (64) 21 (60)
- Not married 106 (39) 30 (47) 25 (40) 17 (30) 20 (36) 14 (40)
Contraceptive use 0.84
- Yes 103 (38) 24 (38) 20 (32) 22 (39) 22 (39) 15 (43)
- No 172 (62) 40 (62) 43 (68) 35 (61) 34 (61) 20 (57)
Condom use
# 0.36
- Yes 3 (1) 2 (3) 0 (0) 1 (2) 0 (0) 0 (0)
- No 272 (99) 30 (97) 63 (100) 56 (98) 56 (100) 35 (100)
Douching 0.22
- Yes 174 (63) 39 (61) 46 (73) 31 (54) 38 (68) 20 (57)
- No 101 (37) 25 (39) 17 (27) 26 (46) 18 (32) 15 (43)
HIV infection 0.19
- Positive 148 (58) 35 (59) 40 (69) 30 (53) 25 (47) 18 (56)
- Negative 111 (42) 24 (41) 18 (31) 27 (47) 28 (53) 14 (44)
Any HPV infection 0.006
- Positive 101 (37) 33 (52) 27 (43) 20 (35) 13 (23) 8 (23)
- Negative 174 (63) 33 (48) 36 (57) 37 (65) 43 (77) 27 (77)
Multiple HPV infection 0.001
- Positive 46 (17) 16 (25) 18 (29) 7 (12) 3 (5) 2 (6)
- Negative 229 (83) 48 (75) 45 (71) 50 (88) 53 (95) 33 (94)
Group 1 HPV infection 0.03
- Positive 61 (22) 21 (33) 17 (27) 12 (21) 8 (14) 3 (9)
- Negative 214 (78) 43 (67) 46 (73) 45 (79) 48 (86) 32 (91)
Group 2a HPV infection 0.18
- Positive 8 (3) 4 (6) 3 (5) 1 (2) 0 (0) 0 (0)
- Negative 267 (97) 60 (94) 60 (95) 56 (98) 56 (100) 35 (10)
Group 2b HPV infection
- Positive 67 (24) 24 (38) 20 (32) 11 (19) 6 (11) 6 (17) 0.004
- Negative 208 (76) 40 (62) 43 (68) 46 (81) 50 (89) 29 (83)
#Consistent condom use in the past 2 years.
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275) of the women studied. The prevalence of group 2a
(Probable carcinogens) HPV type in the study participants
(HPV68) was 3% (8/275). Group 2b HPV types (Possible
carcinogens) were found in 24% (67/275) of the study par-
ticipants. HPV81 and HPV42 were the most prevalent
group 2b types, each was found in 4.7% (13/275) of the
women studied.
Among women who had HPV infection, the age group
distribution was 32% (33/101) for ≤30 years; 27% (27/101)
for 31 – 35 years, 20% (20/101) for age group 36 – 40 years,
13% (13/101) for 41 – 45 years and 8% (8/101) for women
older than 45 years (Table 1). The prevalence curves of
HPV types for each age group are shown in Figure 1. The
prevalence of any HPV infection was significantly reduced
with increasing age. The multivariable PR of any HPV in-
fection was 2.26 (1.17 to 4.34) for the lowest age category
compared with the highest age category (referent group).
This association remained significant for definite carcino-
genic and probable/possible carcinogenic HPV types.
We found multiple HPV infections in 12.7% (35/275) of
the women. Multiple HPV infections were more prevalent
among younger women. Compared to women in the high-
est age group (>45 years), the PR (95% CI) of multiple
HPV infection was 4.38 (1.07, 17.94), 5.00 (1.23, 20.30),
2.15 (0.47, 9.77) and 0.94 (0.16, 5.33), p for linear trend=
0.0004, for age group≤30, 31 – 35, 36 – 40 and 41 – 45,
respectively (Table 2).
The PR (95% CI) of any HPV infection was 2.54 (1.69,
3.81) p=< 0.001, comparing women who were HIV posi-
tive with those who were HIV negative. In multivariable
analysis, we found a significant association between HIV
and prevalent HPV infection, the PR (95% CI) of HIV for
any HPV infection was 2.27 (1.48 to 3.48). HIV status was
also associated with the prevalence of group 1 and group
2 HPV types in multivariable analysis, adjusting for age,
marital status, age at sexual initiation, number of sexual
partners, use of contraceptives, douching and body mass
index. The multivariable adjusted PR (95% CI) was 4.01
(1.96, 8.21) for HIV and group 1 HPV, and 1.87 (1.11 to
3.17) for HIV and group 2 HPV (Table 3).
The multivariable PR (95% CI) of any HPV infection
was 0.96 (0.93 to 1.00), comparing women with BMI ≥
25 kg/m
2 to those with BMI 18.5 -<25 kg/m
2. There
was no significant association between BMI and group 1
or group 2 HPV infections. The multivariable PR (95%
CI) was 0.97 (0.91, 1.02) for BMI and group 1; and 0.97
(0.92, 1.03) for BMI and group 2 HPV infections, com-
paring women with BMI≥ 25 kg/m
2 to those with BMI
18.5 - <25 kg/m
2.
Discussion
In this cross-sectional study of urban Nigerian women,
the prevalence of HPV infection was 37%. We observed
a significant inverse linear association between age and
the prevalence of HPV infections. This prevalence was ap-
proximately 4 times higher in women aged 18 – 30 years
compared to women who were older than 45 years and
younger women were more likely to have carcinogenic
HPV types.
The prevalence of HPV infection among women in our
study population was higher than had been reported in
previous studies from Nigeria. Among 932 women sur-
veyed between 1999 and 2000 in southwestern Nigeria, the
prevalence of HPV was 26.3% [25]. Our finding of
HPV35 as the most prevalent type is similar to findings
from southwest Nigeria and southern Mozambique,
among women without invasive cervical cancer [12,25].
Different trends have been reported on the age preva-
lence of HPV in Africa. The results of some studies showed
there was a high peak of HPV prevalence among younger
women which decreased with age, but among older
women the prevalence either decreased [8,9], reached
a plateau [12,26] or increased [13,14]; whereas one study
Figure 1 Prevalence curves of HPV types, by age group.
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[17]. Studies in rural and semi-rural southwestern Nigeria
showed that the age prevalence of HPV was highest in
younger women, declined with age and reached a plateau
[11] or increased [15] among older women. Although the
variation in age prevalence of HPV is well documented
and appears to largely reflect differences in sexual behav-
ior across geographical regions [7], the difference between
our result and that of the previous studies from Nigeria
may reflect characteristics of the populations surveyed.
We studied an urban population of women in Abuja, cen-
tral Nigeria who presented to hospitals for cervical cancer
screening, while these other studies were community sur-
veys in which participants were visited at their homes in
southwestern Nigeria and asked to participate.
The results of some studies suggests that HIV infection
is a known risk factor for HPV infection [27]. In our study,
we found an association between HIV and HPV infection
and this association remained statistically significant when
we examined the association between HIV and different
categories of HPV. The results of our analyses on HIV and
high-risk HPV infections among Nigerian women have
been previously described [28]. Although the prevalence
of HPV infection appeared to be associated with some
socio-demographic factors, these results did not reach sig-
nificant levels in our multivariable analysis.
We found a marginal inverse association between any
HPV infection and BMI in univariate analysis but this
association was null in multivariable analysis. Prior studies
of the association between body weight and HPV infections
have yielded conflicting results. Among female sexual
workers in Spain, there was an inverse association between
high-risk HPV prevalence and BMI. In contrast, a study
based on the US National Health and Nutrition Examin-
ation Survey (NHANES) showed that BMI was not associ-
ated with prevalence of HPV [29]. The relationship between
BMI and the risk of HPV infection needs further evaluation.
Our study has several important limitations. First, the
sample size was small hence we were unable to examine
the prevalence of HPV infection among women age
60 years and above. We are therefore unable to deter-
mine whether the prevalence of HPV in this study popu-
lation would have continued to fall, remained stable or
risen. Second, because of the cross sectional design of
our study we could not examine temporal trends of po-
tential correlates of HPV and the risk factors for persist-
ent HPV infections. With continued follow up of this
population and repeated sampling, we will be able to re-
port the pattern and spectrum of persistent HPV infec-
tion in Nigeria in future.
Conclusion
The age prevalence pattern of HPV infection among
women in cervical cancer screening programs in Nigeria
is similar to that in many developed countries. Replica-
tion of this study in other urban African populations is
Table 2 HPV prevalence ratios by age strata and carcinogenic risk
HPV Types Age strata (Years) P for
Trend ≤ 30 31 - 35 36 - 40 41 - 45 > 45
N PR (95% CI) N PR (95% CI) N PR (95% CI) N PR (95% CI) N Ref
Any HPV (n=136) 49 2.26 (1.17, 4.34) 40 1.88 (0.96, 3.67) 24 1.54 (0.76, 3.10) 14 1.02 (0.47, 2.20) 9 1.00 0.0003
Multiple HPV (n= 46) 16 4.38 (1.07, 17.94) 18 5.00 (1.23, 20.30) 7 2.15 (0.47, 9.77) 3 0.94 (0.16, 5.33) 2 1.00 0.0004
Group 1 (n=61) 21 3.83 (1.23, 11.94) 17 3.15 (0.99, 10.00) 12 2.46 (0.74, 8.10) 8 1.67 (0.47, 5.86) 3 1.00 0.0014
Group 2* (n= 75) 28 2.19 (0.99, 4.84) 23 1.85 (0.82, 4.18) 12 1.13 (0.46, 2.77) 6 0.62 (0.22, 1.79) 6 1.00 0.0007
*Group 2= Group 2A and 2B.
Table 3 Univariate and multivariable prevalence ratios of potential correlates of HPV positivity
Potential correlates Any HPV Group 1 Group 2*
PR (95% CI) PR (95% CI) PR (95% CI)
Univariate Multivariable Univariate Multivariable Univariate Multivariable
Age 0.96 (0.94, 0.98) 0.98 (0.95, 1.00) 0.95 (0.92, 0.98) 0.96 (0.93, 1.00) 0.95 (0.92, 0.98) 0.97 (0.94, 1.00)
Marital status 1.17 (0.85, 1.59) 0.99 (0.74, 1.32) 1.43 (0.92, 2.22) 1.25 (0.80, 1.95) 1.28 (0.84, 1.94) 1.09 (0.70, 1.68)
Age at sexual initiation 0.98 (0.94, 1.03) 1.00 (0.95, 1.05) 0.96 (0.90, 1.03) 0.98 (0.71, 1.36) 0.98 (0.93, 1.04) 1.00 (0.78, 1.28)
Number of sexual partners 0.99 (0.94, 1.05) 1.01 (0.95, 1.07) 1.02 (0.95, 1.10) 1.04 (0.96, 1.13) 1.00 (0.93, 1.08) 1.01 (0.93, 1.09)
HIV status 2.54 (1.69, 3.81) 2.27 (1.48, 3.48) 3.68 (1.95, 6.92) 4.01 (1.96, 8.21) 2.21 (1.32, 3.67) 1.87 (1.11, 3.17)
Contraceptive use 1.20 (0.86, 1.67) 1.24 (0.89, 1.73) 1.16 (0.72, 1.85) 0.98 (0.60, 1.60) 1.24 (0.79, 1.94) 1.34 (0.83, 2.17)
Douching 0.95 (0.69, 1.32) 1.06 (0.78, 1.44) 1.11 (0.71, 1.75) 1.54 (0.94, 2.52) 0.90 (0.58, 1.39) 1.05 (0.67, 1.66)
Body mass index 0.94 (0.90, 0.97) 0.96 (0.93, 1.00) 0.93 (0.88, 0.98) 0.97 (0.91, 1.02) 0.96 (0.91, 1.01) 0.97 (0.92, 1.03)
*Group 2A and 2B.
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correlates of persistent high risk HPV infection are also
needed. These studies will be useful in providing evi-
dence for policies relating to the use of HPV DNA tests
for screening, utility and coverage of current HPV vac-
cines and allocation of resources for HPV infections and




BMI: Body mass index; CI: Confidence interval; CIN: Cervical intraepithelial
neoplasm; HIV: Human immunodeficiency virus; HPV: Human papillomavirus;
IARC: International Agency for Cancer Research; IHVN: Institute of Human
Virology Nigeria; NHANES: National Health and Nutrition Examination Survey;
PCR: Polymerase Chain Reaction REDCap Research Electronic Data Capture;
PR: Prevalence ratio; SD: Standard deviation.
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